FibroBiologics, Inc. (FBLG) News
Track canonical SquawkNews coverage tagged to FBLG, FibroBiologics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 18 indexed stories across 14 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
FibroBiologics, Inc. (FBLG) Granted European Patent Covering Enhanced Fibroblast Therapies
FibroBiologics, Inc. was granted European Patent No. 3568465 for methods to enhance fibroblast therapeutic activity using platelet rich plasma and cytokines, with claims including angiogenesis and spinal disc regeneratio
NEWS | Sep 29, 2026, 12:31 PM UTC
L
FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity
Newly Granted Patent Covers Methods of Augmenting the Regenerative Efficacy of Fibroblasts Using Platelet Rich Plasma and Cytokines, with Claims Directed to Angiogenesis and Spinal Disc RegenerationHOUSTON, Sept. 29, 202
NEWS | Sep 29, 2026, 12:30 PM UTC
L
FibroBiologics Raises ~$0.5 Million in Private Placement With CSO at $1.675 Per Unit
FibroBiologics entered into a securities purchase agreement with Chief Scientific Officer Hamid Khoja for a private placement of 298,508 shares and accompanying warrants for up to 298,508 additional shares. Units are pri
EQUITY | Sep 15, 2026, 11:23 AM UTC
L
Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications
Learn how FibroBiologics is developing an off-the-shelf therapeutic platform designed to harness the regenerative and immune-modulating properties of fibroblastsManagement to discuss the ongoing Phase 1/2 diabetic foot u
EQUITY | Sep 08, 2026, 01:00 PM UTC
L
FibroBiologics announces new U.S. patent for fibroblast wound healing
FibroBiologics (FBLG) announced issuance of a new U.S. patent covering therapeutic use of fibroblasts in wound healing.
EQUITY | Sep 03, 2026, 12:31 PM UTC
L
FibroBiologics gets new U.S. patent covering fibroblast wound-healing therapy
FibroBiologics said a newly issued U.S. patent covers topical administration of 3D spheroid fibroblasts and fibroblast-derived materials to treat and accelerate healing of wounds.
EQUITY | Sep 03, 2026, 12:30 PM UTC
L
FibroBiologics announces new U.S. patent for degenerative disc disease
FibroBiologics said it has been issued a new U.S. patent covering treatment of degenerative disc disease using fibroblast conditioned media.
EQUITY | Sep 01, 2026, 12:31 PM UTC
L
FibroBiologics announces newly issued U.S. patent for disc regeneration methods
FibroBiologics says a newly issued U.S. patent covers methods of promoting disc regeneration using components derived from stimulated fibroblasts.
EQUITY | Sep 01, 2026, 12:30 PM UTC
L
FibroBiologics releases third batch of CYWC628 drug product
FibroBiologics said it released a third batch of CYWC628 drug product for its Phase 1/2 diabetic foot ulcer clinical trial.
EQUITY | Aug 27, 2026, 12:31 PM UTC
L
FibroBiologics regains Nasdaq trading rules compliance
FibroBiologics (FBLG) said it has regained compliance with Nasdaq trading rules, per TradeXchange Newsdesk.
EQUITY | Aug 26, 2026, 12:30 PM UTC
L
FibroBiologics (FBLG) appoints Leigh Steinberg to board
FibroBiologics (FBLG) appoints Leigh Steinberg to its Board of Directors, according to the company announcement.
REGULATION | Aug 24, 2026, 12:31 PM UTC
M
FibroBiologics says Australian patent accepted for cannabidiol disc therapy
FibroBiologics says an Australian patent has been accepted for cannabidiol adjuvant therapy for the treatment of degenerative disc disease.
REGULATION | Aug 20, 2026, 12:31 PM UTC
L
FibroBiologics (FBLG) reports cartilage repair in preclinical study
FibroBiologics announces chondrocyte spheroids demonstrated cartilage repair in a preclinical study of degenerative joints, with no additional quantitative results or catalyst details provided.
EQUITY | Aug 18, 2026, 12:30 PM UTC
M
FibroBiologics Granted European Patent
FibroBiologics gets patent for cartilage regeneration
EQUITY | Aug 05, 2026, 12:30 PM UTC
L
FBLG - FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate - Click
FBLG - FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate
EARNINGS | Jul 31, 2026, 09:35 PM UTC
M
FBLG Announces $9M Placement
FibroBiologics announces up to $9.0 million private placement priced at-the-market under Nasdaq rules
EQUITY | Jun 26, 2026, 12:31 PM UTC
M
FBLG Receives Patent Notice
FibroBiologics Receives U.S. Patent And Trademark Office Notice Of Allowance For Patented Application Entitled Therapeutic Use Of Fibroblasts In Wound Healing
EQUITY | Jun 22, 2026, 12:35 PM UTC
M
FBLG Receives US Patent
FBLG - FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound HealingAllowed claims directly support the Company's ongoing Phase 1/2 clinical trial of CYWC628 i
EQUITY | Jun 22, 2026, 12:31 PM UTC